SPDR S&P Biotech ETF
314 hedge funds and large institutions have $3.6B invested in SPDR S&P Biotech ETF in 2017 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 116 increasing their positions, 76 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
8% more funds holding
Funds holding: 292 → 314 (+22)
1.67% less ownership
Funds ownership: 97.98% → 96.31% (-1.7%)
42% less call options, than puts
Call options by funds: $826M | Put options by funds: $1.43B
Holders
314
Holding in Top 10
15
Calls
$826M
Puts
$1.43B
Top Buyers
| 1 | +$147M | |
| 2 | +$123M | |
| 3 | +$97M | |
| 4 |
Morgan Stanley
New York
|
+$67.7M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$56.6M |
Top Sellers
| 1 | -$152M | |
| 2 | -$105M | |
| 3 | -$46.4M | |
| 4 |
JPMorgan Chase & Co
New York
|
-$26.8M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$25.2M |